Penn State bioprints bone spheroids that carry a genetic switch for blood vessels

An interdisciplinary team of engineers and chemists at Penn State has bioprinted spheroids, small clusters of living cells, that support bone regeneration and also produce new blood vessels inside the generated tissue ^[1][2]. The team reports verifying this in lab experiments and in mouse models, with the work published in Chemical Engineering Journal ^[3].

The vessels are the whole point. "Without vascularization, conventional tissue generation techniques cannot adequately regenerate bone," said co-corresponding author Ibrahim Ozbolat, a Penn State professor of engineering science and mechanics, biomedical engineering and neurosurgery. "We need vascularization to support the thick bonds found in bone tissue" ^[4][5]. Facilitating that vessel growth has been the difficult part when spheroids are used to make bone ^[6].

The approach installs the instruction before printing rather than hoping the scaffold supplies it. Starting from blank, undifferentiated, commercially sourced stem cells ^[7], the team transfected two strands of microRNA, tiny genetic molecules that can act as a switch to enable or disable a particular characteristic of a cell ^[8]. One strand, miR-148b, helps spur bone growth; the other, miR-210, helps spur vascularization ^[9]. The cells were cultured for a few days and then assembled into spheroids ^[10].

Placement is the second half of the method. Bioprinting conventionally encapsulates cells in a jelly-like hydrogel scaffold that acts as a 3D matrix in which the cells mature into tissue ^[11]. Ozbolat said aspiration-assisted bioprinting, an approach pioneered by his group, picks up individual spheroids and puts them at specific locations in that scaffold ^[12]. Spacing is the variable he cares about: "We want the spheroids to be the same distance apart so that we have uniform regeneration," he said, adding that the same positional control applies to other complex tissues, including lung or pancreas cells ^[13].

Daniel Hayes, the other co-corresponding author and head of biomedical engineering at Penn State, framed the target population narrowly ^[14]. "You wouldn't pursue this treatment for a normal bone break. This is for someone who's had substantial trauma or loss of bone due to cancer or an infection," Hayes said, describing two mechanisms at work: printed progenitor cells that will eventually help form vascularized bone, and the hope that those same cells drive the body's own regenerative process ^[15]. Hayes also framed the underlying problem as differentiation, since every tissue is a combination of cell types that must diverge from a single baseline as they mature ^[16].

What is not in the announcement matters for anyone assessing readiness. Penn State's account carries no vessel density, no defect size, no follow-up duration, and no comparison against an untransfected spheroid control ^[17]. Two microRNAs are also a coarse instrument next to the sequence of signals real bone repair uses, and the release does not claim otherwise ^[18].

Watch for the published paper's numbers on vessel patency and whether the printed vasculature connects to host circulation in the mouse work, since that is the step that separates vessel-like structures from perfusion. Watch, too, for throughput: a method that places spheroids one at a time has to scale to defects measured in centimeters before the trauma and oncology cases Hayes describes are reachable ^[15].